Clinical Trials Sponsored by Aimmune Therapeutics, Inc.

Total 3066 results

Aimmune Therapeutics, Inc.

Completed

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

Peanut Allergy

United States, Canada, Spain, Netherlands, Germany, United Kingdom, Ireland, Sweden, France, Italy
Aimmune Therapeutics, Inc.

Terminated

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Hen Egg Allergy

United States
Aimmune Therapeutics, Inc.

Completed

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (RAMSES)

Peanut Allergy

United States, Canada
Aimmune Therapeutics, Inc.

Terminated

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Peanut Allergy

Spain
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT (ARC001)

Peanut Allergy

United States
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

Peanut Allergy

United States
Aimmune Therapeutics, Inc.

Completed

AR101 Real-World Open-Label Extension Study

Peanut Allergy

United States, Canada
Aimmune Therapeutics, Inc.

Completed

ARTEMIS Peanut Allergy In Children (ARTEMIS)

Peanut Allergy

United Kingdom, Italy, France, Germany, Ireland, Spain, Sweden
Aimmune Therapeutics, Inc.

Completed

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)

Peanut Allergy

United States, United Kingdom, France, Germany
Aimmune Therapeutics, Inc.

Completed

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) (PALISADE)

Peanut Allergy

United States, Spain, Ireland, Netherlands, Canada, United Kingdom, Germany, Denmark, Italy, Sweden
Aimmune Therapeutics, Inc.

Completed

PALISADE Follow-on Study (ARC004)

Peanut Allergy

United States, Spain, Netherlands, Italy, Canada, Germany, Ireland, Sweden, United Kingdom
Immune-Onc Therapeutics

Active, not recruiting

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Solid Tumor, Adult

United States
Immune-Onc Therapeutics

Recruiting

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Advanced Solid Tumor

China
Regeneron Pharmaceuticals
Sanofi; Aimmune Therapeutics, Inc.

Completed

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Peanut Allergy

United States
Immune-Onc Therapeutics
Regeneron Pharmaceuticals

Active, not recruiting

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Timmune Biotech Inc.

Unknown

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy

Non-hodgkin Lymphoma,B Cell

China
Timmune Biotech Inc.

Unknown

Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Non-Hodgkin Lymphoma

China
Immune Biosolutions Inc

Completed

Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

COVID-19

South Africa, Ukraine
Intervene Immune, Inc.

Recruiting

Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial (TRIIM-X)

Immunosenescence | Epigenetic Aging

United States
Immune Biosolutions Inc

Completed

Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness

COVID-19

South Africa, Brazil
Boston Immune Technologies and Therapeutics

Not yet recruiting

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

Peripheral T-cell Lymphoma | NHL | Cutaneous T Cell Lymphoma
Immune Biosolutions Inc

Completed

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

COVID-19

Ukraine, South Africa
Altimmune, Inc.

Completed

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

Healthy Volunteers

United States
Altimmune, Inc.

Completed

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes

United States
Altimmune, Inc.

Completed

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Non-Alcoholic Fatty Liver Disease

United States
Altimmune, Inc.

Completed

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease

United States
Altimmune, Inc.

Completed

ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

NASH - Nonalcoholic Steatohepatitis

Australia
Altimmune, Inc.

Completed

Study of the Safety and Immunogenicity of NasoVAX Extension

Influenza

United States
Altimmune, Inc.

Completed

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

Hepatitis B

Korea, Republic of, United Kingdom
Altimmune, Inc.

Unknown

NasoShield Study of Safety and Immunogenicity (NasoShield)

Healthy Volunteers

United States
Altimmune, Inc.

Active, not recruiting

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Hepatitis B, Chronic

Spain, United Kingdom, Canada, United States, Germany
Calimmune, Inc.

Active, not recruiting

Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients

HIV-1 Infection | Receipt of Cal-1 Modified Hematopoietic Cellular Products

United States
Altimmune, Inc.

Completed

ALT-801 DDI Study in Healthy Volunteers

NASH - Nonalcoholic Steatohepatitis

Australia
Altimmune, Inc.

Terminated

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Coronavirus Infection

United States
Altimmune, Inc.

Recruiting

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial) (IMPACT)

Non-Alcoholic Steatohepatitis (NASH)

Australia, United States, Puerto Rico
Altimmune, Inc.

Completed

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Influenza

United States
Altimmune, Inc.

Completed

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Obesity/Overweight

United States
Calimmune, Inc.

Completed

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

Human Immunodeficiency Virus

United States
Altimmune, Inc.

Completed

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Influenza A Subtype H5N1 Infection

United States
Immune-Onc Therapeutics
California Institute for Regenerative Medicine (CIRM)

Recruiting

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

CMML | AML With Monocytic Differentiation

United States
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors

Neoplasms | Neoplasms by Histologic Type

China
Natural Immune Systems Inc

Recruiting

Clinical Proof-of-concept Study on Immune Surveillance and Alertness

Immune Surveillance

United States
Natural Immune Systems Inc

Recruiting

Antioxidant Bioavailability

Pharmacokinetics

United States
Immune Design
Genentech, Inc.

Terminated

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Sarcoma | Myxoid/Round Cell Liposarcoma | Liposarcoma | Synovial Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma

United States
Natural Immune Systems Inc

Completed

Nutraceutical Support of Fatigue Reduction, Improved Physical, Mental & Cognitive Function and Mitochondrial Function

Fatigue

United States
Natural Immune Systems Inc

Completed

Evaluation of Activity Levels, Inflammatory Markers, and Overall Wellness. (114-012)

Range of Motion

United States
Natural Immune Systems Inc

Completed

CytoQuel: Clinical Documentation on Effects on Chronic Pain, Wellness, and Reduction of Inflammatory Markers

Pain

United States
Alpine Immune Sciences, Inc.

Recruiting

An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)

Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Cold Agglutinin Disease | Warm Autoimmune Hemolytic Anemia

United States, Canada, Australia, Turkey, United Kingdom
Alpine Immune Sciences, Inc.

Recruiting

An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases (RUBY-3)

Lupus Nephritis | Immunoglobulin A Nephropathy | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Membranous Nephropathy

United States, Australia, Korea, Republic of

Clinical Trials Sponsored by Aimmune Therapeutics, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations